NeuroSense Therapeutics Ltd. (NRSN)

$2.1564

-0.09 (-4.16%)
Rating:
Recommendation:
-
Symbol NRSN
Price $2.1564
Beta 0.000
Volume Avg. 3.85M
Market Cap 25.174M
Shares () -
52 Week Range 1.23-8.18
1y Target Est -
DCF Unlevered NRSN DCF ->
DCF Levered NRSN LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 13.34% Neutral
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NRSN news


Healthcare
Biotechnology
NASDAQ Capital Market

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.